sponsored
PatientsVille.com Logo

PatientsVille

Roaccutane Medical Research Studies

Up-to-date List of Roaccutane Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Roaccutane Medical Research Studies

Rank Status Study
1 Unknown  Efficacy and Safety of Low-dose Oral Isotretinoin for Seborrhea
Conditions: Seborrhea;   Seborrheic Dermatitis;   Quality of Life
Interventions: Drug: oral isotretinoin;   Drug: salicylic acid and ciclopirox olamine
Outcome Measures: Sebum secretion rate;   sebum secretion rate;   Oral isotretinoin side effects;   oral isotretinoin side effects
2 Not yet recruiting RA-2 13-cis Retinoic Acid (Isotretinoin)
Conditions: Male Infertility;   Klinefelter's Syndrome;   Y-chromosome Microdeletions
Intervention: Drug: 13-cis retinoic acid
Outcome Measures: Total motile sperm;   13-cis retinoic acid serum level;   Number of Participants with Serious and Non-Serious Adverse effects associated with treatment with 13-cis retinoic acid;   13-cis retinoic acid Seminal Plasma Concentration
3 Recruiting Isotretinoin With or Without Monoclonal Antibody Ch14.18, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Conditions: Disseminated Neuroblastoma;   Localized Resectable Neuroblastoma;   Localized Unresectable Neuroblastoma;   Regional Neuroblastoma;   Stage 4S Neuroblastoma
Interventions: Drug: isotretinoin;   Biological: sargramostim;   Biological: monoclonal antibody Ch14.18;   Biological: aldesleukin;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment;   Other: pharmacological study
Outcome Measures: EFS;   OS;   Change in MRD;   Change in tumor biology;   Incidence of toxicities assessed using Common Terminology Criteria for Adverse Events version 4.0;   Levels of ADCC;   Average level of HACA;   Historical data for the analogous patients;   13-cis-retinoic-acid pharmacokinetic parameters;   Presence of naturally occurring anti-glycan antibodies;   Genotype of Kir/Kir-Ligand;   EFS of patients from the non-randomized portion of the trial;   OS of patients from the non-randomized portion of the trial;   Cardiac repolarization;   Genotype of FcR;   Number of courses of therapy delivered
4 Recruiting Identifying the Genetic Predictors of Severe Acne Vulgaris and the Outcome of Oral Isotretinoin Treatment
Conditions: Acne Vulgaris;   Isotretinoin
Intervention:
Outcome Measures: Therapeutic response to isotretinoin;   Adverse reaccion to isotretinoin
5 Recruiting Lenalidomide and Monoclonal Antibody With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma
Conditions: Disseminated Neuroblastoma;   Localized Unresectable Neuroblastoma;   Recurrent Neuroblastoma;   Regional Neuroblastoma;   Stage 4S Neuroblastoma
Interventions: Drug: lenalidomide;   Biological: monoclonal antibody Ch14.18;   Drug: isotretinoin;   Other: pharmacological study;   Other: laboratory biomarker analysis
Outcome Measures: MTD defined as the highest dose level tested at which 0/6 or 1/6 patients experience dose-limiting toxicity (DLT) graded using the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) criteria, version 4.0;   Recommended phase II dose;   Overall survival;   Event-free survival;   Changes in the levels of T cells, NK cells, monocytes, cytokines, and chemokines;   Changes in levels of HACA (or other genotype) and tumor response;   Pharmacokinetic determinations of lenalidomide;   Changes in TLDA scores;   Overall response
6 Recruiting Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System
Conditions: Untreated Childhood Medulloblastoma;   Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
Interventions: Drug: vorinostat;   Drug: isotretinoin;   Drug: vincristine sulfate;   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: thiotepa;   Procedure: peripheral blood stem cell transplantation;   Radiation: 3-dimensional conformal radiation therapy;   Other: laboratory biomarker analysis
Outcome Measures: Dose-limiting toxicity (DLT) of proposed vorinostat as graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0;   Feasibility in terms of completing 3 courses of induction therapy;   Prognostic value of histopathological classification of pediatric medulloblastoma by single-nucleotide polymorphism (SNP) analysis and gene expression analysis;   Response rate of this approach in patients with measurable residual disease (primary site and/or metastatic sites);   Progression-free survival (PFS);   Overall survival (OS);   Predictive values of biological markers in CSF, plasma and urine in the context of a feasibility study
7 Recruiting Accountability for Cancer Care Through Undoing Racism and Equity
Conditions: Breast Cancer;   Lung Cancer
Interventions: Other: ACCURE Navigator;   Other: Usual Care by Cancer Center Care Team
Outcome Measures: Lung Cancer - Lung Resection Surgery within 4 months of diagnosis Breast Cancer - Completion of surgery, radiation if surgery is breast conserving, and adjuvant chemotherapy (when indicated) within 6 months of diagnosis;   Adherence to scheduled appointments
8 Not yet recruiting Effect of Isotretinoin on Immune Activation Among HIV-1 Infected Subjects With Incomplete CD4+ T Cell Recovery
Condition: HIV-1 Infection
Intervention: Drug: Isotretinoin
Outcome Measures: Change from baseline in CD8+ T-cell activation at week 14/16;   Markers of gut microbial translocation;   Markers of systemic inflammation and coagulation;   Markers of macrophage activation (sCD163);   Peripheral CD4+ T-cell count;   Th17 and Treg frequency;   Cell-associated HIV-1 DNA and RNA;   Endogenous retinoid metabolite profiles;   Primary targeted adverse events;   Pharmacokinetics - Trough concentrations of Isotretinoin and ART
9 Recruiting Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
Conditions: Disseminated Neuroblastoma;   Localized Resectable Neuroblastoma;   Localized Unresectable Neuroblastoma;   Regional Neuroblastoma
Interventions: Drug: doxorubicin hydrochloride;   Other: pharmacological study;   Other: questionnaire administration;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: in vitro-treated peripheral blood stem cell transplantation;   Procedure: therapeutic conventional surgery;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: external beam radiation therapy;   Radiation: intensity-modulated radiation therapy;   Drug: cyclophosphamide;   Drug: topotecan hydrochloride;   Drug: cisplatin;   Drug: etoposide phosphate;   Drug: vincristine sulfate;   Radiation: meta-iodobenzylguanidine (MIBG) labeled with iodine-131;   Drug: busulfan;   Drug: melphalan;   Drug: isotretinoin
Outcome Measures: Proportion of MIBG avid patients treated with meta-iodobenzylguanidine (MIBG) labeled with iodine-131;   Proportion of MIBG avid patients treated with MIBG labeled with iodine-131 and Bu/Mel chemotherapy;   Percentage of average per capita income encompassed by the total of travel + housing + lost wages;   Proportion of eligible high-risk patients accrued to the study;   Event-free survival rate;   Incidence of adverse events and SOS, assessed by Common Terminology Criteria (CTC)v.4.0 for toxicity assessment and grading
10 Unknown  Isotretinoin in Treating Young Patients With High-Risk Neuroblastoma
Condition: Neuroblastoma
Interventions: Drug: isotretinoin;   Genetic: DNA analysis;   Genetic: polymerase chain reaction;   Other: laboratory biomarker analysis;   Other: pharmacological study
Outcome Measures: Pharmacokinetics of isotretinoin;   Toxicity according to NCI CTCAE v.3;   Clinical response
11 Recruiting 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk Neuroblastoma
Condition: Neuroblastoma
Intervention: Drug: 3F8 and 13-cis-retinoic acid
Outcome Measures: Assess the impact of high-dose 3F8/GM-CSF;   Apply real-time quantitative RT-PCR;   Monitor safety of the high-dose antibody treatment
12 Recruiting 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma
Condition: Neuroblastoma
Intervention: Biological: 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid
Outcome Measures: Assess the impact of high-dose 3F8/GM-CSF on relapse-free survival;   Apply real-time quantitative RT-PCR to test the hypothesis that the minimal residual disease content of bone marrow;   Monitor safety of the high-dose antibody treatment
13 Recruiting High Dose Chemotherapy and Autologous Transplant for Neuroblastoma
Condition: Neuroblastoma
Interventions: Drug: Carboplatin;   Biological: Autologous stem cell infusion;   Biological: Granulocyte colony stimulating factor;   Radiation: Radiation therapy;   Drug: Isotretinoin (13-cis-retinoic acid);   Drug: Melphalan;   Drug: Etoposide
Outcome Measures: Number of Patients with Successful Engraftment;   Number of Patients with Disease Free Survival;   Overall Survival;   Number of Patients with Treatment Related Death
14 Unknown  Combination Chemotherapy Followed by Stem Cell Transplant and Isotretinoin in Treating Young Patients With High-Risk Neuroblastoma
Condition: Neuroblastoma
Interventions: Biological: filgrastim;   Drug: carboplatin;   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: dacarbazine;   Drug: doxorubicin hydrochloride;   Drug: etoposide phosphate;   Drug: ifosfamide;   Drug: isotretinoin;   Drug: melphalan;   Drug: topotecan hydrochloride;   Drug: vincristine sulfate;   Drug: vindesine;   Procedure: autologous hematopoietic stem cell transplantation;   Radiation: iobenguane I 131;   Radiation: radiation therapy
Outcome Measures: Event-free survival (EFS);   Overall survival (OS);   Impact of well established clinical and molecular risk factors on EFS and OS;   Early response, measured after 2 courses of induction chemotherapy;   Response to induction therapy, measured before autologous stem cell transplantation;   Toxicity during the first 2 courses and the last 6 courses of induction chemotherapy;   Impact of the extent of initial and best surgery on outcome and frequency of complications;   Acute and late toxicity of radiotherapy;   Correlation of MIBG activity with whole-body radiation dose;   Molecular markers (MYCN and status of chromosome 1p and 11q)
15 Unknown  Combination Chemotherapy With or Without Filgrastim Before Surgery, High-Dose Chemotherapy, and Radiation Therapy Followed by Isotretinoin With or Without Monoclonal Antibody in Treating Patients With Neuroblastoma
Condition: Neuroblastoma
Interventions: Biological: filgrastim;   Biological: monoclonal antibody Ch14.18;   Drug: busulfan;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: isotretinoin;   Drug: melphalan;   Drug: vincristine sulfate;   Procedure: bone marrow ablation with stem cell support;   Procedure: conventional surgery;   Procedure: peripheral blood stem cell transplantation;   Radiation: radiation therapy
Outcome Measures: Event-free survival at 3 years;   Mean number of febrile events during induction;   Response rate assessed by the International Neuroblastoma Response Criteria after 4 and 8 induction chemotherapy courses;   Event-free survival at 5 years;   Overall survival;   Toxicity;   Biological factors (i.e., MycNM amplification, 1p deletion, ploidy, 17 q+, CD44, and Trk-A);   Serum concentrations of lactic dehydrogenase, ferritin, neurone specific enolase;   Urinary catecholamines at diagnosis
16 Recruiting Long Term Continuous Infusion ch14.18/CHO Plus s.c. Aldesleukin (IL-2)
Condition: Neuroblastoma
Interventions: Drug: ch14.18/CHO;   Drug: Aldesleukin;   Drug: Isotretinoin
Outcome Measures: Efficacy endpoint;   Pain-toxicity endpoint;   ADCC and activated NK cell concentrations;   Soluble IL-2 receptor and CDC;   HAMA and HACA;   Absolute lymphocyte count;   Absolute NK cell numbers;   Ch14.18/CHO concentrations;   Anti-tumour response;   Confirmation cohort
17 Recruiting Therapy for Children With Advanced Stage Neuroblastoma
Condition: Neuroblastoma
Interventions: Drug: cyclophosphamide;   Drug: topotecan;   Biological: hu14.18K322A;   Procedure: peripheral blood stem cell harvest;   Procedure: surgical resection;   Drug: cisplatin;   Drug: etoposide;   Drug: doxorubicin;   Drug: vincristine;   Drug: busulfan;   Drug: melphalan;   Biological: peripheral blood stem cell transplantation;   Biological: natural killer cell infusion;   Radiation: radiation therapy;   Biological: GM-CSF;   Biological: G-CSF;   Drug: mesna;   Drug: levetiracetam;   Biological: interleukin-2;   Drug: Isotretinoin
Outcome Measures: Number of participants with complete or partial response;   Failure rate for the 6 cycles of induction therapy.;   Local failure rate;   Dose limiting toxicity (DLT) or severe (grade 3 or 4) VoD;   Dose limiting toxicity (DLT)
18 Recruiting 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone Marrow
Condition: Neuroblastoma
Intervention: Biological: 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic
Outcome Measures: Assess the activity of high-dose 3F8/GM-CSF;   Apply real-time quantitative RT-PCR;   Monitor safety of the high-dose antibody treatment
19 Recruiting Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma
Condition: Neuroblastoma
Interventions: Biological: Anti-GD2 3F8 Monoclonal Antibody;   Drug: GM-CSF (granulocyte-macrophage colony-stimulating factor);   Drug: oral isotretinoin
Outcome Measures: relapse-free survival;   complete remission
20 Recruiting Antiacne Medications Pseudotumor Cerebri
Condition: Optic Disc Swelling
Intervention: Other: Retinal nerve fibre layer measurement
Outcome Measure: Retinal nerve fibre layer

These studies may lead to new treatments and are adding insight into Roaccutane etiology and treatment.

A major focus of Roaccutane research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Roaccutane